Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial.
Tor OlofssonJohan Karlsson WallmanAnna JöudMaria E C SchelinSofia ErnestamRonald van VollenhovenSaedis SaevarsdottirJon LampaPublished in: Arthritis care & research (2021)
Despite active combination treatment, almost one-third of new-onset RA patients reported unacceptable pain after 21 months, and refractory pain constituted more than 4/5 of this pain load. Adding IFX versus SSZ plus HCQ to MTX reduced both cumulative pain and unacceptable pain at 21 months, suggesting less long-term pain for the biologic therapy. These results display insufficient effects of current treatment strategies on inflammation-independent pain components, warranting alternative approaches in affected patients.
Keyphrases
- chronic pain
- rheumatoid arthritis
- pain management
- neuropathic pain
- randomized controlled trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- spinal cord
- spinal cord injury
- stem cells
- prognostic factors
- systematic review
- disease activity
- bone marrow
- ankylosing spondylitis
- postoperative pain
- interstitial lung disease
- peritoneal dialysis
- double blind